INGN · Inogen Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $348.67M | $335.70M | $315.66M | $377.24M | $358.00M | $308.49M |
| Cost of Revenue | $194.40M | $180.96M | $188.96M | $223.71M | $181.52M | $170.31M |
| Gross Profit | $154.26M | $154.74M | $126.70M | $153.53M | $176.48M | $138.18M |
| R&D | $19.40M | $21.61M | $20.84M | $21.94M | $16.58M | $14.08M |
| SG&A | $67.38M | $72.58M | $75.26M | $43.91M | $37.85M | $38.60M |
| Total Operating Expenses | $184.47M | $197.26M | $236.09M | $238.78M | $167.24M | $150.21M |
| D&A | $20.66M | $21.00M | $18.15M | $23.51M | $21.63M | $18.58M |
| Operating Income | ($30.21M) | ($42.52M) | ($109.39M) | ($85.24M) | $9.24M | ($12.03M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | ($632.0K) | ($588.0K) | $105.0K | $504.0K | $14.99M | $549.0K |
| Net Income | ($22.75M) | ($35.89M) | ($102.45M) | ($83.77M) | ($6.33M) | ($5.83M) |
| EPS - Basic | ($0.86) | ($1.52) | ($4.42) | ($3.67) | ($0.28) | ($0.27) |
| EPS - Diluted | ($0.86) | ($1.52) | ($4.42) | ($3.67) | ($0.28) | ($0.27) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $103.73M | $113.80M | $125.49M | $187.01M | $235.52M | $211.96M |
| Accounts Receivable | $38.86M | $29.56M | $42.24M | $62.73M | $24.45M | $29.72M |
| Inventory | $25.97M | $24.81M | $21.84M | $34.09M | $31.87M | $24.82M |
| Accounts Payable | $20.26M | $16.62M | $13.45M | $18.24M | $10.26M | $12.52M |
| Current Assets | $198.30M | $185.45M | $207.07M | $304.64M | $329.19M | $305.70M |
| Total Assets | $298.63M | $296.19M | $326.19M | $405.04M | $489.51M | $461.85M |
| Current Liabilities | $63.53M | $76.69M | $72.50M | $65.35M | $61.51M | $56.71M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $106.39M | $122.33M | $121.38M | $107.64M | $119.29M | $112.23M |
| Stockholders' Equity | $192.23M | $173.86M | $204.81M | $297.41M | $370.23M | $349.62M |
| Retained Earnings | ($175.58M) | ($152.84M) | ($116.95M) | ($14.50M) | $69.27M | $75.61M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($11.22M) | $5.91M | ($3.23M) | ($37.53M) | $23.63M | $37.01M |
| Investing Cash Flow | ($26.21M) | ($13.97M) | ($59.31M) | ($10.88M) | ($14.64M) | ($25.64M) |
| Financing Cash Flow | $24.18M | $265.0K | $960.0K | $380.0K | $15.00M | $2.07M |
| CapEx | $2.52M | $3.36M | $5.22M | $3.34M | $5.48M | $4.38M |
| Free Cash Flow | ($13.74M) | $2.55M | ($8.45M) | ($40.87M) | $18.15M | $32.63M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 44.2% | 46.1% | 40.1% | 40.7% | 49.3% | 44.8% |
| Operating margin | -8.7% | -12.7% | -34.7% | -22.6% | 2.6% | -3.9% |
| EBITDA margin | -2.7% | -6.4% | -28.9% | -16.4% | 8.6% | 2.1% |
| Net margin | -6.5% | -10.7% | -32.5% | -22.2% | -1.8% | -1.9% |
| Free cash flow margin | -3.9% | 0.8% | -2.7% | -10.8% | 5.1% | 10.6% |
| FCF / Net income | 0.60 | -0.07 | 0.08 | 0.49 | -2.87 | -5.60 |
| R&D / Revenue | 5.6% | 6.4% | 6.6% | 5.8% | 4.6% | 4.6% |
| SG&A / Revenue | 19.3% | 21.6% | 23.8% | 11.6% | 10.6% | 12.5% |
| Effective tax rate | - | - | - | - | 173.1% | - |
| Return on assets | -7.6% | -12.1% | -31.4% | -20.7% | -1.3% | -1.3% |
| Return on equity | -11.8% | -20.6% | -50.0% | -28.2% | -1.7% | -1.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.12 | 2.42 | 2.86 | 4.66 | 5.35 | 5.39 |
| Quick ratio | 2.71 | 2.09 | 2.55 | 4.14 | 4.83 | 4.95 |
| Cash ratio | 1.63 | 1.48 | 1.73 | 2.86 | 3.83 | 3.74 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.55 | 1.70 | 1.59 | 1.36 | 1.32 | 1.32 |
| Liabilities / Assets | 0.36 | 0.41 | 0.37 | 0.27 | 0.24 | 0.24 |
| Efficiency | ||||||
| Asset turnover | 1.17 | 1.13 | 0.97 | 0.93 | 0.73 | 0.67 |
| Inventory turnover | 7.49 | 7.29 | 8.65 | 6.56 | 5.70 | 6.86 |
| Days sales outstanding | 41d | 32d | 49d | 61d | 25d | 35d |
| Days inventory outstanding | 49d | 50d | 42d | 56d | 64d | 53d |
| Days payable outstanding | 38d | 34d | 26d | 30d | 21d | 27d |
| Cash conversion cycle | 51d | 49d | 65d | 87d | 68d | 62d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 0.9x | 1.2x | 0.6x | 1.5x | 2.1x | 2.8x |
| P / S | 0.5x | 0.6x | 0.4x | 1.2x | 2.1x | 3.2x |
| EV / EBITDA | - | - | - | - | 17.1x | 117.5x |
| Growth | ||||||
| Revenue growth (YoY) | 3.9% | 6.4% | -16.3% | 5.4% | 16.1% | -14.8% |
| Revenue CAGR (3y) | -2.6% | -2.1% | 0.8% | 1.4% | -0.0% | 7.3% |
| Revenue CAGR (5y) | 2.5% | -1.5% | -2.5% | 8.6% | 12.0% | 14.2% |
| Gross profit growth (YoY) | -0.3% | 22.1% | -17.5% | -13.0% | 27.7% | -19.6% |
| Operating income growth (YoY) | 29.0% | 61.1% | -28.3% | - | - | - |
| Net income growth (YoY) | 36.6% | 65.0% | -22.3% | -1222.8% | -8.6% | - |
| EPS growth (YoY) | 43.4% | 65.6% | -20.4% | -1210.7% | -3.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 79.3% | - | -44.4% | -12.9% |
| FCF CAGR (5y) | - | -41.6% | - | - | -9.1% | -1.9% |
| Book value growth (YoY) | 10.6% | -15.1% | -31.1% | -19.7% | 5.9% | 1.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Geographic
$295.30M totalUS$156.48M · 53.0%
Non Us$138.83M · 47.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.44
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Comparing Inogen Inc against the 5 most active filers in the same SIC group.